公开(公告)号：US20230159633A1

公开(公告)日：2023-05-25

申请号：US17992369

申请日：2022-11-22

Applicant: Janssen Biotech, Inc.

Inventor： Matthew Germinaro ,  Kuan-hsiang Gary Huang ,  Hongyan Zhang

IPC: C07K16/24 ,  A61K45/06 ,  A61K39/395 ,  A61P1/04 ,  A61K31/519 ,  C07K16/28

CPC classification number: C07K16/244 ,  A61K45/06 ,  A61K39/3955 ,  A61P1/04 ,  A61K31/519 ,  C07K16/2887 ,  A61K2039/545

Abstract: A method of treating ulcerative colitis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.

公开(公告)号：US20240199734A1

公开(公告)日：2024-06-20

申请号：US18517248

申请日：2023-11-22

Applicant: Janssen Biotech, Inc.

Inventor： Matthew Germinaro ,  Kuan-hsiang Gary Huang ,  Hongyan Zhang

IPC: C07K16/24 ,  A61K9/00 ,  A61K39/00 ,  A61P1/04

CPC classification number: C07K16/244 ,  A61K9/0019 ,  A61P1/04 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/21

Abstract: A method of treating ulcerative colitis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.